World’s First Human Implant of a 3D-Printed Cornea Restores Sight
December 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Background
Turcot syndrome, also known as Turcot’s syndrome, is a rare genetic disorder that is characterized by the development of tumors in the central nervous system (CNS) and the gastrointestinal (GI) tract. It is named after Dr. Jacques Turcot, a Canadian physician who first described the syndrome in 1959.
Epidemiology
Turcot syndrome is an extremely rare disorder, and accurate epidemiological data on its prevalence and incidence are limited. Due to its rarity, it is challenging to determine the exact number of individuals affected by Turcot syndrome worldwide. However, the available information suggests that Turcot syndrome is a very uncommon condition. Turcot syndrome can occur in both children and adults, but the age of onset can vary depending on the specific gene mutation involved.
In Turcot syndrome type 1 (associated with APC gene mutations), symptoms often appear in childhood or adolescence. Turcot syndrome type 2 (associated with MMR gene mutations) can manifest at a younger age, typically in childhood or early adulthood. The estimated prevalence of familial adenomatous polyposis (FAP), which includes Turcot syndrome type 1, is approximately 1 in 8,000 to 1 in 10,000 individuals. However, it’s important to note that not all individuals with FAP will develop Turcot syndrome.
Regarding Turcot syndrome type 2, which is associated with Lynch syndrome and MMR gene mutations, its prevalence is lower than FAP. Lynch syndrome is estimated to affect around 1 in 300 to 1 in 1,000 individuals in the general population, but again, Turcot syndrome type 2 represents only a subset of individuals with Lynch syndrome. It is worth mentioning that the prevalence of Turcot syndrome may vary among different populations and geographic regions. Some studies have suggested that certain populations, such as individuals of Ashkenazi Jewish descent, may have a higher incidence of specific gene mutations associated with Turcot syndrome.
Due to the rarity of Turcot syndrome, it is crucial to raise awareness among healthcare professionals and genetic counselors to facilitate accurate diagnosis and appropriate management of affected individuals and their families. Genetic testing and counseling play a vital role in identifying individuals at risk, providing genetic counseling, and implementing appropriate surveillance and treatment strategies. As research and genetic testing capabilities continue to advance, a better understanding of the epidemiology and prevalence of Turcot syndrome may emerge. However, at present, it remains a rare and relatively poorly understood condition.
Anatomy
Pathophysiology
The pathophysiology of Turcot syndrome is closely related to the underlying genetic mutations that lead to the development of tumors in the central nervous system (CNS) and gastrointestinal (GI) tract. There are two primary types of Turcot syndrome, each associated with specific gene mutations and molecular pathways.
Turcot syndrome type 1 (TS1) – APC Gene Mutation:
Turcot syndrome type 1 is caused by mutations in the APC (adenomatous polyposis coli) gene. Mutations in APC are also associated with familial adenomatous polyposis (FAP), a condition characterized by the development of multiple polyps in the colon and rectum. In TS1, the loss or alteration of APC function leads to the formation of adenomatous polyps in the GI tract, which can progress to colorectal cancer. These polyps can bleed, leading to chronic anemia and other GI symptoms.
Additionally, individuals with TS1 are at an increased risk of developing tumors in the CNS, particularly medulloblastomas and glioblastomas. The exact mechanisms underlying the development of these CNS tumors in TS1 are not fully understood. However, it is believed that the disruption of the Wnt signaling pathway, which is regulated by the APC gene, plays a crucial role. Dysregulation of Wnt signaling can lead to abnormal cell growth, proliferation, and differentiation in the CNS, contributing to tumor formation.
Turcot syndrome type 2 (TS2) – MMR Gene Mutation:
Turcot syndrome type 2 is associated with mutations in the mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2. These genes play a crucial role in repairing DNA damage and maintaining genomic stability. When MMR genes are mutated, the normal DNA repair mechanism is impaired, leading to an increased risk of DNA replication errors and accumulation of genetic mutations. In TS2, the loss of MMR function predisposes individuals to the development of tumors in the GI tract, including colorectal cancer and other gastrointestinal malignancies.
Similarly, the MMR gene mutations in TS2 are also associated with Lynch syndrome (hereditary non-polyposis colorectal cancer), which increases the risk of various cancers such as colorectal, endometrial, and ovarian cancers. The specific molecular mechanisms by which MMR gene mutations lead to CNS tumor formation in TS2 are not fully understood. It is believed that the loss of MMR function contributes to genomic instability and the accumulation of additional mutations, which can disrupt normal cellular processes in the CNS and promote tumor development.
Etiology
The etiology of Turcot syndrome is primarily attributed to specific gene mutations that increase the susceptibility to tumor development in the central nervous system (CNS) and gastrointestinal (GI) tract. Turcot syndrome is considered a genetic disorder, and two main types have been identified, each associated with distinct gene mutations:
Turcot syndrome type 1 (TS1):
TS1 is primarily caused by mutations in the APC (adenomatous polyposis coli) gene. Mutations in the APC gene are also linked to familial adenomatous polyposis (FAP), a condition characterized by the formation of numerous polyps in the colon and rectum. In TS1, individuals inherit one mutated copy of the APC gene and develop polyps in the GI tract, which can progress to colorectal cancer. Additionally, TS1 is associated with an increased risk of developing tumors in the CNS, such as medulloblastomas and glioblastomas.
Turcot syndrome type 2 (TS2):
TS2 is associated with mutations in the mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2. These genes play a vital role in repairing DNA damage and maintaining genomic stability. When mutations occur in these MMR genes, the ability to repair DNA errors is compromised. This leads to an increased risk of DNA replication errors and the accumulation of genetic mutations. TS2 is also associated with Lynch syndrome, which predisposes individuals to various cancers, including colorectal, endometrial, and ovarian cancers. In TS2, individuals are at an increased risk of developing tumors in the GI tract and CNS, similar to TS1.
It is important to note that Turcot syndrome follows an autosomal recessive pattern of inheritance, meaning that both copies of the respective genes (APC for TS1 or MMR genes for TS2) need to be mutated for the syndrome to manifest. This means that affected individuals inherit one mutated copy of the gene from each of their parents, who are typically unaffected carriers. Genetic testing and counseling are crucial in diagnosing and managing individuals with Turcot syndrome.
Identifying the specific gene mutations involved can assist in determining the risk of developing tumors and tailoring appropriate surveillance and treatment strategies. While the primary etiology of Turcot syndrome is associated with these gene mutations, other genetic and environmental factors may also influence the development and progression of the disorder. Further research is needed to fully understand the complete etiology and potential contributing factors of Turcot syndrome.
Genetics
Prognostic Factors
The prognosis of Turcot syndrome can vary depending on several factors, including the specific type (TS1 or TS2), the age of onset, the extent of tumor involvement, and the individual’s overall health. It is important to note that Turcot syndrome is a rare and complex condition, and individual outcomes can vary significantly.
Turcot Syndrome Type 1 (TS1): The prognosis for individuals with TS1 can be influenced by the development and management of gastrointestinal tumors (polyps and colorectal cancer) and central nervous system (CNS) tumors (medulloblastomas and glioblastomas). With appropriate surveillance and timely intervention, early detection and treatment of tumors can improve outcomes. However, the prognosis can be influenced by the stage, size, and location of tumors, as well as the response to treatment. In some cases, the prognosis for individuals with TS1 can be relatively favorable, especially if tumors are detected early and effectively managed.
Turcot Syndrome Type 2 (TS2): TS2 is associated with an increased risk of colorectal cancer, gastrointestinal tumors, and CNS tumors. The prognosis can vary depending on the specific gene mutation and associated cancer risks. Regular surveillance and screening play a crucial role in detecting tumors early, enabling timely intervention and potentially improving outcomes. However, the prognosis for individuals with TS2 can be influenced by the aggressiveness and stage of tumors, as well as the response to treatment.
It is important to highlight that Turcot syndrome carries an increased risk of developing multiple tumors throughout a person’s lifetime, and long-term management and surveillance are necessary to monitor for tumor recurrence or the development of new tumors. This ongoing surveillance is crucial for early detection and intervention, as it can improve outcomes and increase the chances of successful treatment.
The prognosis of Turcot syndrome can also be influenced by the individual’s overall health, response to treatment, and access to appropriate medical care. Supportive care measures, including psychological support and counseling, can also contribute to the overall well-being and quality of life of individuals with Turcot syndrome and their families.
Given the rarity of Turcot syndrome and the limited data available, it is challenging to provide specific and precise prognostic information for affected individuals. It is crucial for individuals with Turcot syndrome to receive ongoing medical care and monitoring from a multidisciplinary team of healthcare professionals experienced in managing the condition.
Clinical History
Clinical history
The clinical history of Turcot syndrome can vary depending on the specific type (TS1 or TS2) and the individual affected. However, there are several common clinical features and patterns that may be observed in individuals with Turcot syndrome. It is important to note that not all individuals with Turcot syndrome will present with all of these features, and the severity and age of onset can vary.
Gastrointestinal Symptoms:
Individuals with Turcot syndrome may experience gastrointestinal symptoms related to the presence of polyps or tumors in the GI tract. These symptoms can include chronic diarrhea, rectal bleeding, abdominal pain, changes in bowel habits, and anemia due to chronic bleeding. These symptoms are more commonly associated with Turcot syndrome type 1 (TS1) due to the involvement of the APC gene and the development of adenomatous polyps.
Central Nervous System (CNS) Tumors:
Turcot syndrome is characterized by an increased risk of developing tumors in the CNS, particularly in TS1 and TS2. Medulloblastomas and glioblastomas are the most commonly observed CNS tumors in individuals with Turcot syndrome. Symptoms related to CNS tumors can include headaches, seizures, changes in vision, motor and coordination difficulties, behavioral changes, and cognitive impairment. The age of onset for CNS tumors can vary, but they are often seen in childhood or adolescence.
Family History:
Turcot syndrome has an autosomal recessive pattern of inheritance, meaning that affected individuals inherit one mutated copy of the respective gene (APC for TS1 or MMR genes for TS2) from each parent. Therefore, a notable family history of colorectal cancer, brain tumors, or other associated malignancies may be present.
Other Associated Cancers:
In addition to colorectal cancer and CNS tumors, individuals with Turcot syndrome may have an increased risk of developing other malignancies associated with the specific gene mutations involved. For example, TS1 is associated with APC gene mutations, which are also linked to familial adenomatous polyposis (FAP), increasing the risk of colorectal and other gastrointestinal cancers. TS2, which is associated with MMR gene mutations, is also related to Lynch syndrome (hereditary non-polyposis colorectal cancer), increasing the risk of various cancers including colorectal, endometrial, and ovarian cancers.
Other Features:
Additional features that may be observed in individuals with Turcot syndrome can include developmental delays, intellectual disability, and physical anomalies, although these are not as commonly associated with the condition.
Physical Examination
Physical examination
The physical examination findings in individuals with Turcot syndrome can vary depending on the specific type (TS1 or TS2) and the presence of associated manifestations. Here are some aspects that may be assessed during a physical examination:
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
When evaluating a patient with symptoms and signs suggestive of Turcot syndrome, it is essential to consider other conditions that may present with similar features. The following are some of the differential diagnoses to consider:
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
The management of Turcot syndrome requires a multidisciplinary approach involving various medical specialists. The specific management strategies will depend on the type of Turcot syndrome (TS1 or TS2), the presence of tumors, and individual patient factors. Here are some general aspects of the management of Turcot syndrome:
The management of Turcot syndrome should be individualized based on the specific needs of the patient and may require ongoing surveillance and treatment throughout their lifetime. Regular follow-up visits with a team of specialists, including oncologists, geneticists, gastroenterologists, neurologists, and other relevant healthcare professionals, are essential to monitor for tumor development, manage symptoms, and provide appropriate support.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
References
https://www.ncbi.nlm.nih.gov/books/NBK534782/
Turcot syndrome, also known as Turcot’s syndrome, is a rare genetic disorder that is characterized by the development of tumors in the central nervous system (CNS) and the gastrointestinal (GI) tract. It is named after Dr. Jacques Turcot, a Canadian physician who first described the syndrome in 1959.
Turcot syndrome is an extremely rare disorder, and accurate epidemiological data on its prevalence and incidence are limited. Due to its rarity, it is challenging to determine the exact number of individuals affected by Turcot syndrome worldwide. However, the available information suggests that Turcot syndrome is a very uncommon condition. Turcot syndrome can occur in both children and adults, but the age of onset can vary depending on the specific gene mutation involved.
In Turcot syndrome type 1 (associated with APC gene mutations), symptoms often appear in childhood or adolescence. Turcot syndrome type 2 (associated with MMR gene mutations) can manifest at a younger age, typically in childhood or early adulthood. The estimated prevalence of familial adenomatous polyposis (FAP), which includes Turcot syndrome type 1, is approximately 1 in 8,000 to 1 in 10,000 individuals. However, it’s important to note that not all individuals with FAP will develop Turcot syndrome.
Regarding Turcot syndrome type 2, which is associated with Lynch syndrome and MMR gene mutations, its prevalence is lower than FAP. Lynch syndrome is estimated to affect around 1 in 300 to 1 in 1,000 individuals in the general population, but again, Turcot syndrome type 2 represents only a subset of individuals with Lynch syndrome. It is worth mentioning that the prevalence of Turcot syndrome may vary among different populations and geographic regions. Some studies have suggested that certain populations, such as individuals of Ashkenazi Jewish descent, may have a higher incidence of specific gene mutations associated with Turcot syndrome.
Due to the rarity of Turcot syndrome, it is crucial to raise awareness among healthcare professionals and genetic counselors to facilitate accurate diagnosis and appropriate management of affected individuals and their families. Genetic testing and counseling play a vital role in identifying individuals at risk, providing genetic counseling, and implementing appropriate surveillance and treatment strategies. As research and genetic testing capabilities continue to advance, a better understanding of the epidemiology and prevalence of Turcot syndrome may emerge. However, at present, it remains a rare and relatively poorly understood condition.
The pathophysiology of Turcot syndrome is closely related to the underlying genetic mutations that lead to the development of tumors in the central nervous system (CNS) and gastrointestinal (GI) tract. There are two primary types of Turcot syndrome, each associated with specific gene mutations and molecular pathways.
Turcot syndrome type 1 (TS1) – APC Gene Mutation:
Turcot syndrome type 1 is caused by mutations in the APC (adenomatous polyposis coli) gene. Mutations in APC are also associated with familial adenomatous polyposis (FAP), a condition characterized by the development of multiple polyps in the colon and rectum. In TS1, the loss or alteration of APC function leads to the formation of adenomatous polyps in the GI tract, which can progress to colorectal cancer. These polyps can bleed, leading to chronic anemia and other GI symptoms.
Additionally, individuals with TS1 are at an increased risk of developing tumors in the CNS, particularly medulloblastomas and glioblastomas. The exact mechanisms underlying the development of these CNS tumors in TS1 are not fully understood. However, it is believed that the disruption of the Wnt signaling pathway, which is regulated by the APC gene, plays a crucial role. Dysregulation of Wnt signaling can lead to abnormal cell growth, proliferation, and differentiation in the CNS, contributing to tumor formation.
Turcot syndrome type 2 (TS2) – MMR Gene Mutation:
Turcot syndrome type 2 is associated with mutations in the mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2. These genes play a crucial role in repairing DNA damage and maintaining genomic stability. When MMR genes are mutated, the normal DNA repair mechanism is impaired, leading to an increased risk of DNA replication errors and accumulation of genetic mutations. In TS2, the loss of MMR function predisposes individuals to the development of tumors in the GI tract, including colorectal cancer and other gastrointestinal malignancies.
Similarly, the MMR gene mutations in TS2 are also associated with Lynch syndrome (hereditary non-polyposis colorectal cancer), which increases the risk of various cancers such as colorectal, endometrial, and ovarian cancers. The specific molecular mechanisms by which MMR gene mutations lead to CNS tumor formation in TS2 are not fully understood. It is believed that the loss of MMR function contributes to genomic instability and the accumulation of additional mutations, which can disrupt normal cellular processes in the CNS and promote tumor development.
The etiology of Turcot syndrome is primarily attributed to specific gene mutations that increase the susceptibility to tumor development in the central nervous system (CNS) and gastrointestinal (GI) tract. Turcot syndrome is considered a genetic disorder, and two main types have been identified, each associated with distinct gene mutations:
Turcot syndrome type 1 (TS1):
TS1 is primarily caused by mutations in the APC (adenomatous polyposis coli) gene. Mutations in the APC gene are also linked to familial adenomatous polyposis (FAP), a condition characterized by the formation of numerous polyps in the colon and rectum. In TS1, individuals inherit one mutated copy of the APC gene and develop polyps in the GI tract, which can progress to colorectal cancer. Additionally, TS1 is associated with an increased risk of developing tumors in the CNS, such as medulloblastomas and glioblastomas.
Turcot syndrome type 2 (TS2):
TS2 is associated with mutations in the mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2. These genes play a vital role in repairing DNA damage and maintaining genomic stability. When mutations occur in these MMR genes, the ability to repair DNA errors is compromised. This leads to an increased risk of DNA replication errors and the accumulation of genetic mutations. TS2 is also associated with Lynch syndrome, which predisposes individuals to various cancers, including colorectal, endometrial, and ovarian cancers. In TS2, individuals are at an increased risk of developing tumors in the GI tract and CNS, similar to TS1.
It is important to note that Turcot syndrome follows an autosomal recessive pattern of inheritance, meaning that both copies of the respective genes (APC for TS1 or MMR genes for TS2) need to be mutated for the syndrome to manifest. This means that affected individuals inherit one mutated copy of the gene from each of their parents, who are typically unaffected carriers. Genetic testing and counseling are crucial in diagnosing and managing individuals with Turcot syndrome.
Identifying the specific gene mutations involved can assist in determining the risk of developing tumors and tailoring appropriate surveillance and treatment strategies. While the primary etiology of Turcot syndrome is associated with these gene mutations, other genetic and environmental factors may also influence the development and progression of the disorder. Further research is needed to fully understand the complete etiology and potential contributing factors of Turcot syndrome.
The prognosis of Turcot syndrome can vary depending on several factors, including the specific type (TS1 or TS2), the age of onset, the extent of tumor involvement, and the individual’s overall health. It is important to note that Turcot syndrome is a rare and complex condition, and individual outcomes can vary significantly.
Turcot Syndrome Type 1 (TS1): The prognosis for individuals with TS1 can be influenced by the development and management of gastrointestinal tumors (polyps and colorectal cancer) and central nervous system (CNS) tumors (medulloblastomas and glioblastomas). With appropriate surveillance and timely intervention, early detection and treatment of tumors can improve outcomes. However, the prognosis can be influenced by the stage, size, and location of tumors, as well as the response to treatment. In some cases, the prognosis for individuals with TS1 can be relatively favorable, especially if tumors are detected early and effectively managed.
Turcot Syndrome Type 2 (TS2): TS2 is associated with an increased risk of colorectal cancer, gastrointestinal tumors, and CNS tumors. The prognosis can vary depending on the specific gene mutation and associated cancer risks. Regular surveillance and screening play a crucial role in detecting tumors early, enabling timely intervention and potentially improving outcomes. However, the prognosis for individuals with TS2 can be influenced by the aggressiveness and stage of tumors, as well as the response to treatment.
It is important to highlight that Turcot syndrome carries an increased risk of developing multiple tumors throughout a person’s lifetime, and long-term management and surveillance are necessary to monitor for tumor recurrence or the development of new tumors. This ongoing surveillance is crucial for early detection and intervention, as it can improve outcomes and increase the chances of successful treatment.
The prognosis of Turcot syndrome can also be influenced by the individual’s overall health, response to treatment, and access to appropriate medical care. Supportive care measures, including psychological support and counseling, can also contribute to the overall well-being and quality of life of individuals with Turcot syndrome and their families.
Given the rarity of Turcot syndrome and the limited data available, it is challenging to provide specific and precise prognostic information for affected individuals. It is crucial for individuals with Turcot syndrome to receive ongoing medical care and monitoring from a multidisciplinary team of healthcare professionals experienced in managing the condition.
Clinical history
The clinical history of Turcot syndrome can vary depending on the specific type (TS1 or TS2) and the individual affected. However, there are several common clinical features and patterns that may be observed in individuals with Turcot syndrome. It is important to note that not all individuals with Turcot syndrome will present with all of these features, and the severity and age of onset can vary.
Gastrointestinal Symptoms:
Individuals with Turcot syndrome may experience gastrointestinal symptoms related to the presence of polyps or tumors in the GI tract. These symptoms can include chronic diarrhea, rectal bleeding, abdominal pain, changes in bowel habits, and anemia due to chronic bleeding. These symptoms are more commonly associated with Turcot syndrome type 1 (TS1) due to the involvement of the APC gene and the development of adenomatous polyps.
Central Nervous System (CNS) Tumors:
Turcot syndrome is characterized by an increased risk of developing tumors in the CNS, particularly in TS1 and TS2. Medulloblastomas and glioblastomas are the most commonly observed CNS tumors in individuals with Turcot syndrome. Symptoms related to CNS tumors can include headaches, seizures, changes in vision, motor and coordination difficulties, behavioral changes, and cognitive impairment. The age of onset for CNS tumors can vary, but they are often seen in childhood or adolescence.
Family History:
Turcot syndrome has an autosomal recessive pattern of inheritance, meaning that affected individuals inherit one mutated copy of the respective gene (APC for TS1 or MMR genes for TS2) from each parent. Therefore, a notable family history of colorectal cancer, brain tumors, or other associated malignancies may be present.
Other Associated Cancers:
In addition to colorectal cancer and CNS tumors, individuals with Turcot syndrome may have an increased risk of developing other malignancies associated with the specific gene mutations involved. For example, TS1 is associated with APC gene mutations, which are also linked to familial adenomatous polyposis (FAP), increasing the risk of colorectal and other gastrointestinal cancers. TS2, which is associated with MMR gene mutations, is also related to Lynch syndrome (hereditary non-polyposis colorectal cancer), increasing the risk of various cancers including colorectal, endometrial, and ovarian cancers.
Other Features:
Additional features that may be observed in individuals with Turcot syndrome can include developmental delays, intellectual disability, and physical anomalies, although these are not as commonly associated with the condition.
Physical examination
The physical examination findings in individuals with Turcot syndrome can vary depending on the specific type (TS1 or TS2) and the presence of associated manifestations. Here are some aspects that may be assessed during a physical examination:
When evaluating a patient with symptoms and signs suggestive of Turcot syndrome, it is essential to consider other conditions that may present with similar features. The following are some of the differential diagnoses to consider:
The management of Turcot syndrome requires a multidisciplinary approach involving various medical specialists. The specific management strategies will depend on the type of Turcot syndrome (TS1 or TS2), the presence of tumors, and individual patient factors. Here are some general aspects of the management of Turcot syndrome:
The management of Turcot syndrome should be individualized based on the specific needs of the patient and may require ongoing surveillance and treatment throughout their lifetime. Regular follow-up visits with a team of specialists, including oncologists, geneticists, gastroenterologists, neurologists, and other relevant healthcare professionals, are essential to monitor for tumor development, manage symptoms, and provide appropriate support.
https://www.ncbi.nlm.nih.gov/books/NBK534782/
Turcot syndrome, also known as Turcot’s syndrome, is a rare genetic disorder that is characterized by the development of tumors in the central nervous system (CNS) and the gastrointestinal (GI) tract. It is named after Dr. Jacques Turcot, a Canadian physician who first described the syndrome in 1959.
Turcot syndrome is an extremely rare disorder, and accurate epidemiological data on its prevalence and incidence are limited. Due to its rarity, it is challenging to determine the exact number of individuals affected by Turcot syndrome worldwide. However, the available information suggests that Turcot syndrome is a very uncommon condition. Turcot syndrome can occur in both children and adults, but the age of onset can vary depending on the specific gene mutation involved.
In Turcot syndrome type 1 (associated with APC gene mutations), symptoms often appear in childhood or adolescence. Turcot syndrome type 2 (associated with MMR gene mutations) can manifest at a younger age, typically in childhood or early adulthood. The estimated prevalence of familial adenomatous polyposis (FAP), which includes Turcot syndrome type 1, is approximately 1 in 8,000 to 1 in 10,000 individuals. However, it’s important to note that not all individuals with FAP will develop Turcot syndrome.
Regarding Turcot syndrome type 2, which is associated with Lynch syndrome and MMR gene mutations, its prevalence is lower than FAP. Lynch syndrome is estimated to affect around 1 in 300 to 1 in 1,000 individuals in the general population, but again, Turcot syndrome type 2 represents only a subset of individuals with Lynch syndrome. It is worth mentioning that the prevalence of Turcot syndrome may vary among different populations and geographic regions. Some studies have suggested that certain populations, such as individuals of Ashkenazi Jewish descent, may have a higher incidence of specific gene mutations associated with Turcot syndrome.
Due to the rarity of Turcot syndrome, it is crucial to raise awareness among healthcare professionals and genetic counselors to facilitate accurate diagnosis and appropriate management of affected individuals and their families. Genetic testing and counseling play a vital role in identifying individuals at risk, providing genetic counseling, and implementing appropriate surveillance and treatment strategies. As research and genetic testing capabilities continue to advance, a better understanding of the epidemiology and prevalence of Turcot syndrome may emerge. However, at present, it remains a rare and relatively poorly understood condition.
The pathophysiology of Turcot syndrome is closely related to the underlying genetic mutations that lead to the development of tumors in the central nervous system (CNS) and gastrointestinal (GI) tract. There are two primary types of Turcot syndrome, each associated with specific gene mutations and molecular pathways.
Turcot syndrome type 1 (TS1) – APC Gene Mutation:
Turcot syndrome type 1 is caused by mutations in the APC (adenomatous polyposis coli) gene. Mutations in APC are also associated with familial adenomatous polyposis (FAP), a condition characterized by the development of multiple polyps in the colon and rectum. In TS1, the loss or alteration of APC function leads to the formation of adenomatous polyps in the GI tract, which can progress to colorectal cancer. These polyps can bleed, leading to chronic anemia and other GI symptoms.
Additionally, individuals with TS1 are at an increased risk of developing tumors in the CNS, particularly medulloblastomas and glioblastomas. The exact mechanisms underlying the development of these CNS tumors in TS1 are not fully understood. However, it is believed that the disruption of the Wnt signaling pathway, which is regulated by the APC gene, plays a crucial role. Dysregulation of Wnt signaling can lead to abnormal cell growth, proliferation, and differentiation in the CNS, contributing to tumor formation.
Turcot syndrome type 2 (TS2) – MMR Gene Mutation:
Turcot syndrome type 2 is associated with mutations in the mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2. These genes play a crucial role in repairing DNA damage and maintaining genomic stability. When MMR genes are mutated, the normal DNA repair mechanism is impaired, leading to an increased risk of DNA replication errors and accumulation of genetic mutations. In TS2, the loss of MMR function predisposes individuals to the development of tumors in the GI tract, including colorectal cancer and other gastrointestinal malignancies.
Similarly, the MMR gene mutations in TS2 are also associated with Lynch syndrome (hereditary non-polyposis colorectal cancer), which increases the risk of various cancers such as colorectal, endometrial, and ovarian cancers. The specific molecular mechanisms by which MMR gene mutations lead to CNS tumor formation in TS2 are not fully understood. It is believed that the loss of MMR function contributes to genomic instability and the accumulation of additional mutations, which can disrupt normal cellular processes in the CNS and promote tumor development.
The etiology of Turcot syndrome is primarily attributed to specific gene mutations that increase the susceptibility to tumor development in the central nervous system (CNS) and gastrointestinal (GI) tract. Turcot syndrome is considered a genetic disorder, and two main types have been identified, each associated with distinct gene mutations:
Turcot syndrome type 1 (TS1):
TS1 is primarily caused by mutations in the APC (adenomatous polyposis coli) gene. Mutations in the APC gene are also linked to familial adenomatous polyposis (FAP), a condition characterized by the formation of numerous polyps in the colon and rectum. In TS1, individuals inherit one mutated copy of the APC gene and develop polyps in the GI tract, which can progress to colorectal cancer. Additionally, TS1 is associated with an increased risk of developing tumors in the CNS, such as medulloblastomas and glioblastomas.
Turcot syndrome type 2 (TS2):
TS2 is associated with mutations in the mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2. These genes play a vital role in repairing DNA damage and maintaining genomic stability. When mutations occur in these MMR genes, the ability to repair DNA errors is compromised. This leads to an increased risk of DNA replication errors and the accumulation of genetic mutations. TS2 is also associated with Lynch syndrome, which predisposes individuals to various cancers, including colorectal, endometrial, and ovarian cancers. In TS2, individuals are at an increased risk of developing tumors in the GI tract and CNS, similar to TS1.
It is important to note that Turcot syndrome follows an autosomal recessive pattern of inheritance, meaning that both copies of the respective genes (APC for TS1 or MMR genes for TS2) need to be mutated for the syndrome to manifest. This means that affected individuals inherit one mutated copy of the gene from each of their parents, who are typically unaffected carriers. Genetic testing and counseling are crucial in diagnosing and managing individuals with Turcot syndrome.
Identifying the specific gene mutations involved can assist in determining the risk of developing tumors and tailoring appropriate surveillance and treatment strategies. While the primary etiology of Turcot syndrome is associated with these gene mutations, other genetic and environmental factors may also influence the development and progression of the disorder. Further research is needed to fully understand the complete etiology and potential contributing factors of Turcot syndrome.
The prognosis of Turcot syndrome can vary depending on several factors, including the specific type (TS1 or TS2), the age of onset, the extent of tumor involvement, and the individual’s overall health. It is important to note that Turcot syndrome is a rare and complex condition, and individual outcomes can vary significantly.
Turcot Syndrome Type 1 (TS1): The prognosis for individuals with TS1 can be influenced by the development and management of gastrointestinal tumors (polyps and colorectal cancer) and central nervous system (CNS) tumors (medulloblastomas and glioblastomas). With appropriate surveillance and timely intervention, early detection and treatment of tumors can improve outcomes. However, the prognosis can be influenced by the stage, size, and location of tumors, as well as the response to treatment. In some cases, the prognosis for individuals with TS1 can be relatively favorable, especially if tumors are detected early and effectively managed.
Turcot Syndrome Type 2 (TS2): TS2 is associated with an increased risk of colorectal cancer, gastrointestinal tumors, and CNS tumors. The prognosis can vary depending on the specific gene mutation and associated cancer risks. Regular surveillance and screening play a crucial role in detecting tumors early, enabling timely intervention and potentially improving outcomes. However, the prognosis for individuals with TS2 can be influenced by the aggressiveness and stage of tumors, as well as the response to treatment.
It is important to highlight that Turcot syndrome carries an increased risk of developing multiple tumors throughout a person’s lifetime, and long-term management and surveillance are necessary to monitor for tumor recurrence or the development of new tumors. This ongoing surveillance is crucial for early detection and intervention, as it can improve outcomes and increase the chances of successful treatment.
The prognosis of Turcot syndrome can also be influenced by the individual’s overall health, response to treatment, and access to appropriate medical care. Supportive care measures, including psychological support and counseling, can also contribute to the overall well-being and quality of life of individuals with Turcot syndrome and their families.
Given the rarity of Turcot syndrome and the limited data available, it is challenging to provide specific and precise prognostic information for affected individuals. It is crucial for individuals with Turcot syndrome to receive ongoing medical care and monitoring from a multidisciplinary team of healthcare professionals experienced in managing the condition.
Clinical history
The clinical history of Turcot syndrome can vary depending on the specific type (TS1 or TS2) and the individual affected. However, there are several common clinical features and patterns that may be observed in individuals with Turcot syndrome. It is important to note that not all individuals with Turcot syndrome will present with all of these features, and the severity and age of onset can vary.
Gastrointestinal Symptoms:
Individuals with Turcot syndrome may experience gastrointestinal symptoms related to the presence of polyps or tumors in the GI tract. These symptoms can include chronic diarrhea, rectal bleeding, abdominal pain, changes in bowel habits, and anemia due to chronic bleeding. These symptoms are more commonly associated with Turcot syndrome type 1 (TS1) due to the involvement of the APC gene and the development of adenomatous polyps.
Central Nervous System (CNS) Tumors:
Turcot syndrome is characterized by an increased risk of developing tumors in the CNS, particularly in TS1 and TS2. Medulloblastomas and glioblastomas are the most commonly observed CNS tumors in individuals with Turcot syndrome. Symptoms related to CNS tumors can include headaches, seizures, changes in vision, motor and coordination difficulties, behavioral changes, and cognitive impairment. The age of onset for CNS tumors can vary, but they are often seen in childhood or adolescence.
Family History:
Turcot syndrome has an autosomal recessive pattern of inheritance, meaning that affected individuals inherit one mutated copy of the respective gene (APC for TS1 or MMR genes for TS2) from each parent. Therefore, a notable family history of colorectal cancer, brain tumors, or other associated malignancies may be present.
Other Associated Cancers:
In addition to colorectal cancer and CNS tumors, individuals with Turcot syndrome may have an increased risk of developing other malignancies associated with the specific gene mutations involved. For example, TS1 is associated with APC gene mutations, which are also linked to familial adenomatous polyposis (FAP), increasing the risk of colorectal and other gastrointestinal cancers. TS2, which is associated with MMR gene mutations, is also related to Lynch syndrome (hereditary non-polyposis colorectal cancer), increasing the risk of various cancers including colorectal, endometrial, and ovarian cancers.
Other Features:
Additional features that may be observed in individuals with Turcot syndrome can include developmental delays, intellectual disability, and physical anomalies, although these are not as commonly associated with the condition.
Physical examination
The physical examination findings in individuals with Turcot syndrome can vary depending on the specific type (TS1 or TS2) and the presence of associated manifestations. Here are some aspects that may be assessed during a physical examination:
When evaluating a patient with symptoms and signs suggestive of Turcot syndrome, it is essential to consider other conditions that may present with similar features. The following are some of the differential diagnoses to consider:
The management of Turcot syndrome requires a multidisciplinary approach involving various medical specialists. The specific management strategies will depend on the type of Turcot syndrome (TS1 or TS2), the presence of tumors, and individual patient factors. Here are some general aspects of the management of Turcot syndrome:
The management of Turcot syndrome should be individualized based on the specific needs of the patient and may require ongoing surveillance and treatment throughout their lifetime. Regular follow-up visits with a team of specialists, including oncologists, geneticists, gastroenterologists, neurologists, and other relevant healthcare professionals, are essential to monitor for tumor development, manage symptoms, and provide appropriate support.
https://www.ncbi.nlm.nih.gov/books/NBK534782/
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
